Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2011-06-07
2011-06-07
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S234100
Reexamination Certificate
active
07955601
ABSTRACT:
An immunogenic agent which comprises a killed strain ofBurkholderia pseudomallei, or a combination of components thereof which combination produces a protective immune response in an animal to whom it is administered, and which comprises at least two members selected from the group consisting of (i) a lipopolysaccharide ofBurkholderia pseudomallei, (ii) a capsular polysaccharide ofBurkholderia pseudomalleiand (iii) a protein ofBurkholderia pseudomalleior an immunogenic variant thereof or an immunogenic fragment of either of these, or a nucleic acid which expresses said protein, immunogenic variant or immunogenic fragment thereof in a host animal; for use in the prevention or treatment of infection byBurkholderia pseudomalleiand/orBurkholderia mallei.
REFERENCES:
patent: 4879213 (1989-11-01), Fox et al.
patent: 5338543 (1994-08-01), Fitzgerald et al.
patent: 5565205 (1996-10-01), Petersen et al.
patent: 6429199 (2002-08-01), Krieg et al.
patent: 2010/0055123 (2010-03-01), Harland
patent: 2010/0062022 (2010-03-01), Harding et al.
patent: 0 761 819 (1997-03-01), None
patent: 2345061 (2000-06-01), None
patent: WO-9710351 (1997-03-01), None
patent: WO 00/56282 (2000-09-01), None
patent: WO 00/56361 (2000-09-01), None
patent: WO 00/56362 (2000-09-01), None
patent: WO 01/55398 (2001-08-01), None
patent: WO 03/073351 (2003-09-01), None
patent: WO 2004/006857 (2004-01-01), None
patent: WO 2006/109071 (2006-10-01), None
patent: WO 2006/109071 (2006-10-01), None
Plotkin et al (Vaccines, W. B. Saunders Co. 1988, p. 571).
Cooper et al (Vaccine vol. 22, pp. 3136-3143, 2004).
Garmory, et al., ‘ATP-Binding Cassette Transporters Are Targets for the Development of Antibacterial Vaccines and Therapies,’Infection and Immunity, 72(12):6757-6763 (2004) XP-002399895.
Higgins, et al., ‘ABC Transporters: From Microorganisms to Man,’Annu. Rev. Cell Biol., 8:67-113 (1992).
Holden, et al., Genomic plasticity of the causative agent of melioidosis,Burkholderia pseudomallei, Proc. Natl. Acad. Sci., 101(39):14240-14245 (2004).
Database EMBL Sep. 16, 2004 ‘Burkholderia pseudomalleistrain K96243, chromosome 1, complete sequence,’ XP002399907 retrieved from EBI accession No. EM—PRO:BX571965 Database accession No. BX571965.
Database EMBL Sep. 16, 2004 ‘Burkholderia pseudomalleistrain K96243, chromosome 2, complete sequence’ XP002399908 retrieved from EBI accession No. EM—PRO:BX571966 Database accession No. BX571966 abstract.
Database UniProt Oct. 25, 2004 ‘Putative lipoprotein releasing system transmembrane protein’ XP002399909 retrieved from EBI accession No. UNIPROT;Q63SP3—BURPS Database accession No. Q63SP3 abstract.
Database UniProt Oct. 25, 2004 ‘Putrescine-bindinng periplasmic protein’ XP002399910 retrieved from EBI accession No. UNIPROT;Q63UP1—BURPS Database accession No. Q63UP1 abstract.
Database UniProt Oct. 25, 2004 ‘Pitative periplasmic oligopeptide-binding protein’ XP002399911 retrieved from EBI accession No. UNIPROT:Q63IDO—BURPS Database accession No. Q63IDO abstract.
Nierman, et al., ‘Structural flexibility in theBurkholderia malleigenome,’Proc. Natl. Acad. Sci., 101(39):14246-14251 (2004).
Woo, et al., ‘Cloning and characterisation ofmalE in Burkholderia pseudomallei,’ J. Med. Microbiol., 50:330-338 (2001) XP 002399893.
Anuntagool, et al., ‘Antigenic Heterogeneity of Lipopolysaccharide AmongBurkholderia pseudomalleiClinical Isolates,’Southeast Asian J. Trop. Med. Public Health, 31(Suppl. 1):146-152 (2000).
Anuntagool, et al., ‘Lipopolysaccharide from Nonvirulent Ara+Burkholderia pseudomalleiIsolates Is Immunologically Indistinguishable from Lipopolysaccharide from Virulent Ara−Clinical Isolates,’Clinical and Diagnostic Laboratory Immunology, 5(2):225-229 (1998).
Atkins, et al., ‘Characterisation of an acapsular mutant ofBurkholderia pseudomalleiidentified by signature tagged mutagenesis,’Journal Medical Microbiology, 51:539-547 (2002).
Brett, et al., ‘Structural and Immunological Characterization ofBurkholderia pseumalleiO-Polysaccharide-Flagellin Protein Conjugates,’Infection and Immunity, 64(7):2824-2828 (1996).
Brett, et al., ‘Pathogenesis of and immunity to melioidosis,’Acta Tropica, 74:201-210 (2000).
Bryan, et al., ‘Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated fromPseudomonas pseudomallei,’ Can. J. Infect. Dis., 5(4):170-178 (1994).
Elvin, et al., ‘Protection against HeterologousBurkholderia pseudomalleiStrains by Dendritic Cell Immunization,’Infection and Immunity, 74(3):1706-1711 (2006).
Golovliov, et al., ‘Cytokine Expression in the Liver during the Early Phase of Murine Tularemia,’Infection and Immunity, 63(2):534-538 (1995).
Healey, et al., Humoral and Cell-Mediated Adaptive Immune Responses Are Required for Protection againstBurkholderia pseudomalleiChallenge and Bacterial Clearance Postinfection,Infection and Immunity, 73(9):5945-5951 (2005).
Ho, et al., ‘Specificity and Functional Activity of Anti-Burkholderia pseudomalleiPolysaccharide Antibodies,’Infection and Immunity, 65(9):3648-3653 (1997).
Holden, et al., ‘Genomic plasticity of the causative agent of melioidosis,Burkholderia pseudomallei,’ PNAS, 101(39):14240-14245 (2004).
Isshiki, et al., Separation of 6-deoxy-heptane from a smooth-type lipopolysaccharide preparation ofBurkholderia pseudomallei, FEMS Microbiol. Lett., 199:21-25 (2001).
Jakob, et al., ‘Activation of Cutaneous Dendritic Cells by CpG-Containing Oligodeoxynucleotides: A Role for Dendritic Cells in the Augmentation of Th1 Responses by Immunostimulatory DNA1,’The Journal of Immunology, 161:3042-3049 (1998).
Jones, et al., ‘Passive protection againstBurkholderia pseudomalleiinfection in mice by monoclonal antibodies against capsular polysaccharide, lipopolysaccharide or proteins,’J. Med. Microbiol., 51:1055-1062 (2002).
Le, et al.,‘Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers,’Vaccine, 18:1893-1901 (2000).
Lipman, et al., Rapid and Sensitive Protein Similarity Searches,Science, 227:1435-1441 (1985).
Matsuura, et al., ‘Biological activities of lipopolysaccharide ofBurkholderia(Pseudomonas)pseudomallei,’ FEMS Microbiol. Lett., 137:79-83 (1996).
Nelson, et al., ‘Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis,’Journal of Medical Microbiology, 53:1177-1182 (2004).
Reckseidler, et al., ‘Detection of Bacterial Virulence Genes by Subtractive Hybridization: Identification of Capsular Polysaccharide ofBurkholderia pseudomalleias a Major Virulence Determinant,’Infection and Immunity, 69(1):34-44 (2001).
Reckseidler-Zenteno, et al., ‘The Capsular Polysaccharide ofBurkholderia pseudomalleiContributes to Survival in Serum by Reducing Complement Factor C3b Deposition,’Infection and Immunity, 73(2):1106-1115 (2005).
Reed and Muench, ‘A Simple Method of Estimating Fifty Per Cent Endpoints,’Am. J. Hygiene, 27(3):493-497 (1938).
Sizemore, et al., ‘Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization,’Vaccine, 15(8):804-807 (1997).
Titball, et al., ‘Vaccination against bubonic and pneumonic plague,’Vaccine, 19(30):4175-4184 (2001).
Ulett, et al., ‘A model of immunity toBurkholderia pseudomallei: unique responses following immunization and acute lethal infection,’Macrobes and Infection, 7:1263-1275 (2005).
Velez, et al.,Trans. R. Soc. Trop. Med. Hyg., 99(8):593-598 (2005).
Warawa, et al., ‘Melioidosis vaccines,’Expert Rev. Vaccines, 1(4):477-482 (2002).
NCBI Database Accession No. YP—110850, Sep. 1, 2004.
NCBI Database Accession No. YP—110888, Sep.
Atkins Timothy Philip
Elvin Stephen John
Eyles James Edward
Healey Gareth David
Nelson Michelle
Kilpatrick Townsend & Stockton LLP
Navarro Mark
The Secretary of State for Defence
LandOfFree
Immunogenic agents against Burkholderia psudomallei and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic agents against Burkholderia psudomallei and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic agents against Burkholderia psudomallei and/or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2691906